The Role of Breast Cancer Cells in Bone Metastasis: Suitable Seeds for Nourishing Soil

1.

Meek ES. The cellular distribution of deoxyribonucleic acid in primary and secondary growths of human breast cancer. J Pathol Bacteriol. 1961;82:167–76. https://doi.org/10.1002/path.1700820120.CrossRefPubMed

2.

Obenauf AC, Massague J. Surviving at a distance: organ-specific metastasis. Trends Cancer. 2015;1(1):76–91. https://doi.org/10.1016/j.trecan.2015.07.009.CrossRefPubMedCentralPubMed

3.

Barriere G, Riouallon A, Renaudie J, Tartary M, Rigaud M. Mesenchymal and stemness circulating tumor cells in early breast cancer diagnosis. BMC Cancer. 2012;12:7. https://doi.org/10.1186/1471-2407-12-114.CrossRef

4.

Lin DF, Shen LS, Luo M, Zhang K, Li JF, Yang Q, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6(1):24. https://doi.org/10.1038/s41392-021-00817-8.CrossRef

5.

König T, Dogan S, Höhn AK, Weydandt L, Aktas B, Nel I. Multi-parameter analysis of disseminated tumor cells (DTCs) in early breast cancer patients with hormone-receptor-positive tumors. Cancers. 2023;15(3):21. https://doi.org/10.3390/cancers15030568.CrossRef

6.

Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409–24. https://doi.org/10.1038/s41571-019-0187-3.CrossRefPubMed

7.

Riethdorf S, Wikman H, Pantel K. Review: Biological relevance of disseminated tumor cells in cancer patients. Int J Cancer. 2008;123(9):1991–2006. https://doi.org/10.1002/ijc.23825.CrossRefPubMed

8.

Braun S, Vogl FD, Naume B, Janni W, Osborne MP, Coombes RC, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353(8):793–802. https://doi.org/10.1056/NEJMoa050434.CrossRefPubMed

9.

Dasgupta A, Lim AR, Ghajar CM. Circulating and disseminated tumor cells: harbingers or initiators of metastasis? Mol Oncol. 2017;11(1):40–61. https://doi.org/10.1002/1878-0261.12022.CrossRefPubMedCentralPubMed

10.

• Yip RKH, Rimes JS, Capaldo BD, Vaillant F, Mouchemore KA, Pal B, et al. Mammary tumour cells remodel the bone marrow vascular microenvironment to support metastasis. Nat Commun. 2021;12(1):17. https://doi.org/10.1038/s41467-021-26556-6. This study describes where metastatic breast cancer cells preferentially settle and the mechanisms by which they reshape the bone microenvironment.

11.

Zhang WJ, Bado I, Wang H, Lo HC, Zhang XHF. Bone metastasis: find your niche and fit in. Trends Cancer. 2019;5(2):95–110. https://doi.org/10.1016/j.trecan.2018.12.004.CrossRefPubMedCentralPubMed

12.

Zhang Y, Luo GJ, Yu XJ. Cellular Communication in bone homeostasis and the related anti-osteoporotic drug development. Curr Med Chem. 2020;27(7):1151–69. https://doi.org/10.2174/0929867325666180801145614.CrossRefPubMed

13.

Liang YR, Zhang HW, Song XJ, Yang QF. Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol. 2020;60:14–27. https://doi.org/10.1016/j.semcancer.2019.08.012.CrossRefPubMed

14.

Allocca G, Hughes R, Wang N, Brown HK, Ottewell PD, Brown NJ, et al. The bone metastasis niche in breast cancer: potential overlap with the haematopoietic stem cell niche in vivo. J Bone Oncol. 2019;17:13. https://doi.org/10.1016/j.jbo.2019.100244.CrossRef

15.

Braga M, Leow CH, Gil JH, Teh JH, Carroll L, Long NJ, et al. Investigating CXCR4 expression of tumor cells and the vascular compartment: a multimodal approach. PLoS ONE. 2021;16(11):21. https://doi.org/10.1371/journal.pone.0260186.CrossRef

16.

Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. Immunity. 2006;25(6):977–88. https://doi.org/10.1016/j.immuni.2006.10.016.

17.

Clézardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, et al. Bonemetastasis: mechanisms, therapies, and biomarkers. Physiol Rev. 2021;101(3):797–855. https://doi.org/10.1152/physrev.00012.2019.CrossRefPubMed

18.

Hira VVV, Van Noorden CJF, Carraway HE, Maciejewskic JP, Molenaar RJ. Novel therapeutic strategies to target leukemic cells that hijack compartmentalized continuous hematopoietic stem cell niches. Biochim Biophys Acta-Rev Cancer. 2017;1868(1):183–98. https://doi.org/10.1016/j.bbcan.2017.03.010.CrossRefPubMed

19.

Shiozawa Y, Pedersen EA, Havens AM, Jung YH, Mishra A, Joseph J, et al. Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest. 2011;121(4):1298–312. https://doi.org/10.1172/jci43414.CrossRefPubMedCentralPubMed

20.

Devignes CS, Aslan Y, Brenot A, Devillers A, Schepers K, Fabre S, et al. HIF signaling in osteoblast-lineage cells promotes systemic breast cancer growth and metastasis in mice. Proc Natl Acad Sci U S A. 2018;115(5):E992–1001. https://doi.org/10.1073/pnas.1718009115.CrossRefPubMedCentralPubMed

21.

•• Sun J, Hu L, Bok S, Yallowitz AR, Cung M, McCormick J, et al. A vertebral skeletal stem cell lineage driving metastasis. Nature. 2023;621(7979):602-9. https://doi.org/10.1038/s41586-023-06519-1. An important study showing the reason why vertebras are more likely to attract breast cancer cells than lime bones.

22.

Zhang H, Wang H, Liu P, Yao Z, Hao X. Expression of Preprotachykinin-I (PPT-I), Neurokinin-1 (NK-1) and neurokinin-2 (NK-2) in breast cancer cells improves tumor cell survival in bone marrow in the early stage of metastasis. Clin Oncol Cancer Res. 2009;6(3):225–32. https://doi.org/10.1007/s11805-009-0225-5.CrossRef

23.

Satriyo PB, Bamodu OA, Chen JH, Aryandono T, Haryana SM, Yeh CT, et al. Cadherin 11 Inhibition Downregulates beta-catenin, deactivates the canonical WNT signalling pathway and suppresses the cancer stem cell-like phenotype of triple negative breast cancer. J Clin Med. 2019;8(2):17. https://doi.org/10.3390/jcm8020148.CrossRef

24.

Tamura D, Hiraga T, Myoui A, Yoshikawa H, Yoneda T. Cadherin-11-mediated interactions with bone marrow stromal/osteoblastic cells support selective colonization of breast cancer cells in bone. Int J Oncol. 2008;33(1):17–24.PubMed

25.

Wang H, Yu CJ, Gao X, Welte T, Muscarella AM, Tian L, et al. The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell. 2015;27(2):193–210. https://doi.org/10.1016/j.ccell.2014.11.017.CrossRefPubMedCentralPubMed

26.

Sinha G, Ferrer AI, Ayer S, El-Far MH, Pamarthi SH, Naaldijk Y, et al. Specific N-cadherin-dependent pathways drive human breast cancer in bone marrow. Life Sci Alliance. 2021;4(7):22. https://doi.org/10.26508/lsa.202000969.

27.

Infante M, Fabi A, Cognetti F, Gorini S, Caprio M, Fabbri A. RANKL/RANK/OPG system beyond bone remodeling: involvement in breast cancer and clinical perspectives. J Exp Clin Cancer Res. 2019;38:18. https://doi.org/10.1186/s13046-018-1001-2.CrossRef

28.

Yue ZY, Niu X, Yuan ZJ, Qin Q, Jiang WH, He L, et al. RSPO2 and RANKL signal through LGR4 to regulate osteoclastic premetastatic niche formation and bone metastasis. J Clin Invest. 2022;132(2):20. https://doi.org/10.1172/jci144579.CrossRef

29.

Zhuang XQ, Zhang H, Li XY, Li XX, Cong M, Peng FL, et al. Differential effects on lung and bone metastasis of breast cancer by Wnt signalling inhibitor DKK1. Nat Cell Biol. 2017;19(10):1274-+. https://doi.org/10.1038/ncb3613.

30.

Nutter F, Holen I, Brown HK, Cross SS, Evans CA, Walker M, et al. Different molecular profiles are associated with breast cancer cell homing compared with colonisation of bone: evidence using a novel bone-seeking cell line. Endocr-Relat Cancer. 2014;21(2):327–41. https://doi.org/10.1530/erc-13-0158.CrossRefPubMed

31.

Tulotta C, Lefley DV, Freeman K, Gregory WM, Hanby AM, Heath PR, et al. Endogenous production of IL1B by breast cancer cells drives metastasis and colonization of the bone microenvironment. Clin Cancer Res. 2019;25(9):2769–82. https://doi.org/10.1158/1078-0432.Ccr-18-2202.CrossRefPubMed

32.

Tulotta C, Lefley DV, Moore CK, Amariutei AE, Spicer-Hadlington AR, Quayle LA, et al. IL-1B drives opposing responses in primary tumours and bone metastases; harnessing combination therapies to improve outcome in breast cancer. npj Breast Cancer. 2021;7(1):15. https://doi.org/10.1038/s41523-021-00305-w.

33.

Bidwell BN, Slaney CY, Withana NP, Forster S, Cao Y, Loi S, et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat Med. 2012;18(8):1224–31. https://doi.org/10.1038/nm.2830.CrossRefPubMed

34.

Rautela J, Baschuk N, Slaney CY, Jayatilleke KM, Xiao K, Bidwell BN, et al. Loss of host type-I IFN signaling accelerates metastasis and impairs NK-cell antitumor function in multiple models of breast cancer. Cancer Immunol Res. 2015;3(11):1207–17. https://doi.org/10.1158/2326-6066.Cir-15-0065.CrossRefPubMed

35.

Slaney CY, Moller A, Hertzog PJ, Parker BS. The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone. OncoImmunology. 2013;2(1):3. https://doi.org/10.4161/onci.22339.CrossRef

36.

Aceto N, Bardia A, Wittner B, Donaldson MC, O’Keefe R, Engstrom A, et al. AR Expression in breast cancer CTCs associates with bone metastases. Mol Cancer Res. 2018;16(4):720–7. https://doi.org/10.1158/1541-7786.Mcr-17-0480.CrossRefPubMedCentralPubMed

37.

Santana-Codina N, Carretero R, Sanz-Pamplona R, Cabrera T, Guney E, Oliva B, et al. A Transcriptome-proteome integrated network identifies endoplasmic reticulum thiol oxidoreductase (ERp57) as a hub that mediates bone metastasis. Mol Cell Proteomics. 2013;12(8):2111–25. https://doi.org/10.1074/mcp.M112.022772.CrossRefPubMedCentralPubMed

38.

Mo YL, Leung LL, Mak CSL, Wang XY, Chan WS, Hui LMN, et al. Tumor-secreted exosomal miR-141 activates tumor-stroma interactions and controls premetastatic niche formation in ovarian cancer metastasis. Mol Cancer. 2023;22(1):21. https://doi.org/10.1186/s12943-022-01703-9.CrossRef

39.

Wang Y, Li YQ, Zhong JP, Li M, Zhou YJ, Lin Q, et al. Tumor-derived Cav-1 promotes pre-metastatic niche formation and lung metastasis in breast cancer. Theranostics. 2023;13(5):1684–97. https://doi.org/10.7150/thno.79250.CrossRefPubMedCentralPubMed

40.

Morrissey SM, Zhang F, Ding CL, Montoya-Durango DE, Hu XL, Yang CH, et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. Cell Metab. 2021;33(10):2040-+. https://doi.org/10.1016/j.cmet.2021.09.002.

41.

Gong Z, Li Q, Shi JY, Wei J, Li PS, Chang CH, et al. Lung fibroblasts facilitate pre-metastatic niche formation by remodeling the local immune microenvironment. Immunity. 2022;55(8):1483-+. https://doi.org/10.1016/j.immuni.2022.07.001.

42.

Zeng ZC, Li YL, Pan YJ, Lan XL, Song FY, Sun JB, et al. Cancer-derived exosomal miR-25-3p promotes pre-metastatic niche formation by inducing vascular permeability and angiogenesis. Nat Commun. 2018;9:14. https://doi.org/10.1038/s41467-018-07810-w.CrossRef

43.

Murgai M, Ju W, Eason M, Kline J, Beury DW, Kaczanowska S, et al. KLF4-dependent perivascular cell plasticity mediates pre-metastatic niche formation and metastasis. Nat Med. 2017;23(10):1176-+. https://doi.org/10.1038/nm.4400.

44.

Costa-Silva B, Aiello NM, Ocean AJ, Singh S, Zhang HY, Thakur BK, et al. Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. Nat Cell Biol. 2015;17(6):816-+. https://doi.org/10.1038/ncb3169.

45.

Wong GL, Abu Jalboush S, Lo HW. Exosomal microRNAs and organotropism in breast cancer metastasis. Cancers. 2020;12(7):24. https://doi.org/10.3390/cancers12071827.CrossRef

46.

Reynaud C, Ferreras L, Di Mauro P, Kan C, Croset M, Bonnelye E, et al. Lysyl oxidase is a strong determinant of tumor cell colonization in bone. Cancer Res. 2017;77(2):268–78. https://doi.org/10.1158/0008-5472.Can-15-2621.CrossRefPubMed

47.

•• Wu KR, Feng JM, Lyu F, Xing F, Sharma S, Liu Y, et al. Exosomal miR-19a and IBSP cooperate to induce osteolytic bone metastasis of estrogen receptor-positive breast cancer. Nat Commun. 2021;12(1):18. https://doi.org/10.1038/s41467-021-25473-y. This study shows how ER-positive breast cancer cells create an osteolytic microenvironment and the mentioned exosomal factors can serve as biomarker for predicting bone metastasis.

48.

• Yuan XX, Qian NS, Ling SK, Li YH, Sun WJ, Li JW, et al. Breast cancer exosomes contribute to pre-metastatic niche formation and promote bone metastasis of tumor cells. Theranostics. 2021;11(3):1429-45. https://doi.org/10.7150/thno.45351. An important studying showing how breast cancer cells educate the bone marrow before they leave the primary lesion for later colonization by exosomes.

49.

Guo L, Zhu Y, Li LD, Zhou SF, Yin GH, Yu GH, et al. Breast cancer cell-derived exosomal miR-20a-5p promotes the proliferation and differentiation of osteoclasts by targeting SRCIN1. Cancer Med. 2019;8(12):5687–701. https://doi.org/10.1002/cam4.2454.CrossRefPubMedCentralPubMed

50.

Tiedemann K, Sadvakassova G, Mikolajewicz N, Juhas M, Sabirova Z, Tabaries S, et al. Exosomal release of L-plastin by breast cancer cells facilitates metastatic bone osteolysis. Transl Oncol. 2019;12(3):462–74. https://doi.org/10.1016/j.tranon.2018.11.014.CrossRefPubMed

51.

Li XQ, Zhang R, Lu H, Yue XM, Huang YF. Extracellular vesicle-packaged CDH11 and ITGA5 induce the premetastatic niche for bone colonization of breast cancer cells. Cancer Res. 2022;82(8):1560–74. https://doi.org/10.1158/0008-5472.Can-21-1331.CrossRefPubMed

52.

Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Mark MT, et al. Tumour exosome integrins determine organotropic metastasis. Nature. 2015;527(7578):329-+. https://doi.org/10.1038/nature15756.

53.

Naseri Z, Oskuee RK, Forouzandeh-moghadam M, Jaafari MR. Delivery of LNA-antimiR-142-3p by mesenchymal stem cells-derived exosomes to breast cancer stem cells reduces tumorigenicity. Stem Cell Rev Rep. 2020;16(3):541–56. https://doi.org/10.1007/s12015-019-09944-w.CrossRefPubMed

54.

Naseri Z, Oskuee RK, Jaafari MR, Moghadam MF. Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo. Int J Nanomed. 2018;13:7727–47. https://doi.org/10.2147/ijn.S182384.CrossRef

55.

Plebanek MP, Mutharasan RK, Volpert O, Matov A, Gatlin JC, Thaxton CS. Nanoparticle targeting and cholesterol flux through scavenger receptor type B-1 inhibits cellular exosome uptake. Sci Rep. 2015;5:14. https://doi.org/10.1038/srep15724.CrossRef

56.

Henrich SE, McMahon KM, Plebanek MP, Calvert AE, Feliciano TJ, Parrish S, et al. Prostate cancer extracellular vesicles mediate intercellular communication with bone marrow cells and promote metastasis in a cholesterol-dependent manner. J Extracell Vesicles. 2020;10(2):17. https://doi.org/10.1002/jev2.12042.CrossRef

57.

Cox TR, Rumney RMH, Schoof EM, Perryman L, Hoye AM, Agrawal A, et al. The hypoxic cancer secretome induces pre-metastatic bone lesions through lysyl oxidase. Nature. 2015;522(7554):106-U279. https://doi.org/10.1038/nature14492.CrossRefPubMedCentralPubMed

58.

Xu YR, Zhang SX, Liao XY, Li M, Chen SW, Li XC, et al. Circular RNA circIKBKB promotes breast cancer bone metastasis through sustaining NF-kappa B/bone remodeling factors signaling. Mol Cancer. 2021;20(1):18. https://doi.org/10.1186/s12943-021-01394-8.CrossRef

59.

Monteiro AC, Bonomo A. CD8(+) T cells from experimental in situ breast carcinoma interfere with bone homeostasis. Bone. 2021;150:13. https://doi.org/10.1016/j.bone.2021.116014.CrossRef

60.

Monteiro AC, Bonomo A. Dendritic cells development into osteoclast-type APCs by 4T1 breast tumor T cells milieu boost bone consumption. Bone. 2021;143:12. https://doi.org/10.1016/j.bone.2020.115755.CrossRef

61.

Bidard FC, Vincent-Salomon A, Sigal-Zafrani B, Dieras V, Mathiot C, Mignot L, et al. Prognosis of women with stage IV breast cancer depends on detection of circulating tumor cells rather than disseminated tumor cells. Ann Oncol. 2008;19(3):496–500. https://doi.org/10.1093/annonc/mdm507.CrossRefPubMed

62.

Hayes DF, Cristofanilli M, Budd GT, Ellis MJ, Stopeck A, Miller MC, et al. Circulating tumor cells at each follow-up time point during therapy of metastatic breast cancer patients predict progression-free and overall survival. Clin Cancer Res. 2006;12(14):4218–24. https://doi.org/10.1158/1078-0432.Ccr-05-2821.CrossRefPubMed

63.

Magbanua MJM, Yau C, Wolf DM, Lee JS, Chattopadhyay A, Scott JH, et al. Synchronous detection of circulating tumor cells in blood and disseminated tumor cells in bone marrow predicts adverse outcome in early breast cancer. Clin Cancer Res. 2019;25(17):5388–97. https://doi.org/10.1158/1078-0432.Ccr-18-3888.CrossRefPubMedCentralPubMed

64.

Liu L, Chen X, Wang Y, Qu Z, Lu Q, Zhao J, et al. Notch3 is important for TGF-beta-induced epithelial-mesenchymal transition in non-small cell lung cancer bone metastasis by regulating ZEB-1. Cancer Gene Ther. 2014;21(9):364–72. https://doi.org/10.1038/cgt.2014.39.CrossRefPubMed

65.

Ghahhari NM, Sznurkowska MK, Hulo N, Bernasconi L, Aceto N, Picard D. Cooperative interaction between ER alpha and the EMT-inducer ZEB1 reprograms breast cancer cells for bone metastasis. Nat Commun. 2022;13(1):19. https://doi.org/10.1038/s41467-022-29723-5.CrossRef

66.

Jiang HM, Zhou C, Zhang Z, Wang Q, Wei HM, Shi W, et al. Jagged1-Notch1-deployed tumor perivascular niche promotes breast cancer stem cell phenotype through Zeb1. Nat Commun. 2020;11(1):16. https://doi.org/10.1038/s41467-020-18860-4.CrossRef

67.

Kudo-Saito C, Fuwa T, Murakami K, Kawakami Y. Targeting FSTL1 Prevents tumor bone metastasis and consequent immune dysfunction. Cancer Res. 2013;73(20):6185–93. https://doi.org/10.1158/0008-5472.Can-13-1364.CrossRefPubMed

68.

Kudo-Saito C. FSTL1 promotes bone metastasis by causing immune dysfunction. OncoImmunology. 2013;2(11):2. https://doi.org/10.4161/onci.26528.CrossRef

69.

• Hu YL, Xu WM, Zeng H, He ZL, Lu X, Zuo DM, et al. OXPHOS-dependent metabolic reprogramming prompts metastatic potential of breast cancer cells under osteogenic differentiation. Br J Cancer. 2020;123(11):1644-55. https://doi.org/10.1038/s41416-020-01040-y. An important study investigating the relationship between the metabolic pathway and metastatic potential.

70.

Scimeca M, Urbano N, Bonfiglio R, Schillaci O, Bonanno E. Breast osteoblast-like cells: a new biomarker for the management of breast cancer. Br J Cancer. 2018;119(9):1129–32. https://doi.org/10.1038/s41416-018-0255-y.CrossRefPubMedCentralPubMed

71.

Yu Y, Xiao CH, Tan LD, Wang QS, Li XQ, Feng YM. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-beta signalling. Br J Cancer. 2014;110(3):724–32. https://doi.org/10.1038/bjc.2013.768.CrossRefPubMed

72.

Sharma T, Kapoor A, Mandal CC. Duality of bone morphogenetic proteins in cancer: a comprehensive analysis. J Cell Physiol. 2022;237(8):3127–63. https://doi.org/10.1002/jcp.30785.CrossRefPubMed

73.

Liu M, Sui LJ, Fang ZQ, Jiang WG, Ye L. Aberrant expression of bone morphogenetic proteins in the disease progression and metastasis of breast cancer. Front Oncol. 2023;13:17. https://doi.org/10.3389/fonc.2023.1166955.CrossRef

74.

Zhang L, Qu JK, Qi YT, Duan YM, Huang YW, Zhou ZF, et al. EZH2 engages TGF beta signaling to promote breast cancer bone metastasis via integrin beta 1-FAK activation. Nat Commun. 2022;13(1):16. https://doi.org/10.1038/s41467-022-30105-0.CrossRef

75.

• Esposito M, Fang C, Cook KC, Park N, Wei Y, Spadazzi C, et al. TGF-beta-induced DACT1 biomolecular condensates repress Wnt signalling to promote bone metastasis. Nat Cell Biol. 2021;23(3):257-+. https://doi.org/10.1038/s41556-021-00641-w. This is an interesting study showing how TGF-beta affects Wnt signaling to promote bone metastasis and includes a novel phase separation mechanism.

76.

Butti R, Nimma R, Kundu G, Bulbule A, Kumar TVS, Gunasekaran VP, et al. Tumor-derived osteopontin drives the resident fibroblast to myofibroblast differentiation through Twist1 to promote breast cancer progression. Oncogene. 2021;40(11):2002–17. https://doi.org/10.1038/s41388-021-01663-2.CrossRefPubMed

77.

Kong LX, Guo SF, Liu CF, Zhao YL, Feng C, Liu YS, et al. Overexpression of SDF-1 activates the NF-kappa B pathway to induce epithelial to mesenchymal transition and cancer stem cell-like phenotypes of breast cancer cells. Int J Oncol. 2016;48(3):1085–94. https://doi.org/10.3892/ijo.2016.3343.CrossRefPubMed

78.

Yang F, Takagaki Y, Yoshitomi Y, Ikeda T, Li JP, Kitada M, et al. Inhibition of dipeptidyl peptidase-4 accelerates epithelial-mesenchymal transition and breast cancer metastasis via the CXCL12/CXCR4/mTOR axis. Cancer Res. 2019;79(4):735–46. https://doi.org/10.1158/0008-5472.Can-18-0620.CrossRefPubMed

79.

Shan SM, Lv Q, Zhao YL, Liu CF, Sun YY, Xi KM, et al. Wnt/beta-catenin pathway is required for epithelial to mesenchymal transition in CXCL12 over expressed breast cancer cells. Int J Clin Exp Pathol. 2015;8(10):12357–67.PubMedCentralPubMed

80.

Yu Y, Luo W, Yang ZJ, Chi JR, Li YR, Ding Y, et al. miR-190 suppresses breast cancer metastasis by regulation of TGF-beta-induced epithelial-mesenchymal transition. Mol Cancer. 2018;17:12. https://doi.org/10.1186/s12943-018-0818-9.CrossRef

81.

Xue YB, Xu WJ, Zhao W, Wang W, Zhang DH, Wu P. miR-381 inhibited breast cancer cells proliferation, epithelial-to-mesenchymal transition and metastasis by targeting CXCR4. Biomed Pharmacother. 2017;86:426–33. https://doi.org/10.1016/j.biopha.2016.12.051.CrossRefPubMed

82.

Roato I, Vitale M. The uncovered role of immune cells and NK cells in the regulation of bone metastasis. Front Endocrinol. 2019;10:9. https://doi.org/10.3389/fendo.2019.00145.CrossRef

83.

Midavaine E, Cote JM, Sarret P. The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers. Cancer Metastasis Rev. 2021;40(2):427–45. https://doi.org/10.1007/s10555-021-09974-2.CrossRefPubMed

84.

Duan LX, Lu YK, Xie WM, Nong L, Jia YX, Tan AH, et al. Leptin promotes bone metastasis of breast cancer by activating the SDF-1/CXCR4 axis. Aging-US. 2020;12(16):16172–82.CrossRef

85.

Masuda T, Endo M, Yamamoto Y, Odagiri H, Kadomatsu T, Nakamura T, et al. ANGPTL2 increases bone metastasis of breast cancer cells through enhancing CXCR4 signaling. Sci Rep. 2015;5:12. https://doi.org/10.1038/srep09170.CrossRef

86.

Hinton CV, Avraham S, Avraham HK. Role of the CXCR4/CXCL12 signaling axis in breast cancer metastasis to the brain. Clin Exp Metastasis. 2010;27(2):97–105. https://doi.org/10.1007/s10585-008-9210-2.CrossRefPubMed

87.

Greenbaum A, Hsu YMS, Day RB, Schuettpelz LG, Christopher MJ, Borgerding JN, et al. CXCL12 in early mesenchymal progenitors is. required for haematopoietic stem-cell maintenance. Nature. 2013;495(7440):227–30. https://doi.org/10.1038/nature11926.

88.

Muller A, Homey B, Soto H, Ge NF, Catron D, Buchanan ME, et al. Involvement of chemokine receptors in breast cancer metastasis. Nature. 2001;410(6824):50–6. https://doi.org/10.1038/35065016.CrossRefPubMed

89.

Xiang LS, Gilkes DM. The contribution of the immune system in bone metastasis pathogenesis. Int J Mol Sci. 2019;20(4):21. https://doi.org/10.3390/ijms20040999.CrossRef

90.

Gelsomino L, Giordano C, La Camera G, Sisci D, Marsico S, Campana A, et al. Leptin signaling contributes to aromatase inhibitor resistant breast cancer cell growth and activation of macrophages. Biomolecules. 2020;10(4):20. https://doi.org/10.3390/biom10040543.CrossRef

91.

Zhang J, Pang YX, Xie T, Zhu LL. CXCR4 antagonism in combination with IDO1 inhibition weakens immune suppression and inhibits tumor growth in mouse breast cancer bone metastases. OncoTargets Ther. 2019;12:4985–92. https://doi.org/10.2147/ott.S200643.CrossRef

92.

Martinez-Ordonez A, Seoane S, Cabezas P, Eiro N, Sendon-Lago J, Macia M, et al. Breast cancer metastasis to liver and lung is facilitated by Pit-1-CXCL12-CXCR4 axis. Oncogene. 2018;37(11):1430–44. https://doi.org/10.1038/s41388-017-0036-8.CrossRefPubMed

93.

Sung V, Stubbs JT 3rd, Fisher L, Aaron AD, Thompson EW. Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol. 1998;176(3):482–94. https://doi.org/10.1002/(sici)1097-4652(199809)176:3%3c482::Aid-jcp5%3e3.0.Co;2-k.CrossRefPubMed

94.

Pang XC, Gong K, Zhang XD, Wu SL, Cui YM, Qian BZ. Osteopontin as a multifaceted driver of bone metastasis and drug resistance. Pharmacol Res. 2019;144:235–44. https://doi.org/10.1016/j.phrs.2019.04.030.CrossRefPubMed

95.

Carter RZ, Micocci KC, Natoli A, Redvers RP, Paquet-Fifield S, Martin A, et al. Tumour but not stromal expression of beta 3 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer. J Pathol. 2015;235(5):760–72. https://doi.org/10.1002/path.4490.CrossRefPubMed

96.

Wang J, Wang L, Xia B, Yang CH, Lai HW, Chen XD. BSP gene silencing inhibits migration, invasion, and bone metastasis of MDA-MB-231BO human breast cancer cells. PLoS ONE. 2013;8(5):8. https://doi.org/10.1371/journal.pone.0062936.CrossRef

97.

Pio GM, Xia Y, Piaseczny MM, Chu JE, Allan AL. Soluble bone-derived osteopontin promotes migration and stem-like behavior of breast cancer cells. PLoS ONE. 2017;12(5):20. https://doi.org/10.1371/journal.pone.0177640.CrossRef

98.

Mine S, Fujisaki T, Kawahara C, Tabata T, Iida T, Yasuda M, et al. Hepatocyte growth factor enhances adhesion of breast cancer cells to endothelial cells in vitro through up-regulation of CD44. Exp Cell Res. 2003;288(1):189–97. https://doi.org/10.1016/s0014-4827(03)00184-8.CrossRefPubMed

99.

Chu JE, Xia Y, Chin-Yee B, Goodale D, Croker AK, Allan AL. Lung-derived factors mediate breast cancer cell migration through CD44 receptor-ligand interactions in a novel ex vivo system for analysis of organ-specific soluble proteins. Neoplasia. 2014;16(2):180-+. https://doi.org/10.1593/neo.132076.

100.

Salvador F, Llorente A, Gomis RR. From latency to overt bone metastasis in breast cancer: potential for treatment and prevention. J Pathol. 2019;249(1):6–18. https://doi.org/10.1002/path.5292.CrossRefPubMedCentralPubMed

101.

Pareek A, Singh OP, Yogi V, Ghori HU, Tiwari V, Redhu P. Bone metastases incidence and its correlation with hormonal and human epidermal growth factor receptor 2 neu receptors in breast cancer. J Canc Res Ther. 2019;15(5):971–5. https://doi.org/10.4103/jcrt.JCRT_235_18.CrossRef

102.

Amanatullah DF, Tamaresis JS, Chu P, Bachmann MH, Hoang NM, Collyar D, et al. Local estrogen axis in the human bone microenvironment regulates estrogen receptor-positive breast cancer cells. Breast Cancer Res. 2017;19:16. https://doi.org/10.1186/s13058-017-0910-x.CrossRef

103.

Clements ME, Johnson RW. PREX1 drives spontaneous bone dissemination of ER plus breast cancer cells. Oncogene. 2020;39(6):1318–34. https://doi.org/10.1038/s41388-019-1064-3.CrossRefPubMed

104.

Johnson RW, Fingers EC, Olcina MM, Vilalta M, Aguilera T, Miao Y, et al. Induction of LIFR confers a dormancy phenotype in breast cancer cells disseminated to the, bone marrow. Nat Cell Biol. 2016;18(10):1078–89. https://doi.org/10.1038/ncb3408.CrossRefPubMedCentralPubMed

105.

Chen DH, Sun YT, Wei YK, Zhang PJ, Rezaeian AH, Teruya-Feldstein J, et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med. 2012;18(10):1511-U105. https://doi.org/10.1038/nm.2940.CrossRefPubMedCentralPubMed

106.

Romero-Moreno R, Curtis KJ, Coughlin TR, Miranda-Vergara MC, Dutta S, Natarajan A, et al. The CXCL5/CXCR2 axis is sufficient to promote breast cancer colonization during bone metastasis. Nat Commun. 2019;10:14. https://doi.org/10.1038/s41467-019-12108-6.CrossRef

107.

Qadi AA, Taberlay PC, Phillips JL, Young A, West AC, Brettingham-Moore KH, et al. The leukemia inhibitory factor receptor gene is a direct target of RUNX1. J Cell Biochem. 2016;117(1):49–58. https://doi.org/10.1002/jcb.25246.CrossRefPubMed

108.

Li YS, Zhang HY, Zhao Y, Wang CY, Cheng ZG, Tang LN, et al. A mandatory role of nuclear PAK4-LIFR axis in breast-to-bone metastasis of ER alpha-positive breast cancer cells. Oncogene. 2019;38(6):808–21. https://doi.org/10.1038/s41388-018-0456-0.CrossRefPubMed

109.

Tang LN, Gao YL, Song YQ, Li Y, Li YS, Zhang HY, et al. PAK4 phosphorylating RUNX1 promotes ER alpha-positive breast cancer-induced osteolytic bone destruction. Int J Biol Sci. 2020;16(12):2235–47. https://doi.org/10.7150/ijbs.47225.CrossRefPubMedCentralPubMed

110.

Omokehinde T, Jotte A, Johnson RW. gp130 cytokines activate novel signaling pathways and alter bone dissemination in ER plus breast cancer cells. J Bone Miner Res. 2022;37(2):185–201. https://doi.org/10.1002/jbmr.4430.CrossRefPubMed

111.

Covert H, Mellor LF, Wolf CL, Ankenbrandt N, Emathinger JM, Tawara K, et al. OSM-induced CD44 contributes to breast cancer metastatic potential through cell detachment but not epithelial-mesenchymal transition. Cancer Manag Res. 2019;11:7721–37. https://doi.org/10.2147/cmar.S208721.CrossRefPubMedCentralPubMed

112.

Tawara K, Bolin C, Koncinsky J, Kadaba S, Covert H, Sutherland C, et al. OSM potentiates preintravasation events, increases CTC counts, and promotes breast cancer metastasis to the lung. Breast Cancer Res. 2018;20:18. https://doi.org/10.1186/s13058-018-0971-5.CrossRef

113.

Fornetti J, Welm AL, Stewart SA. Understanding the bone in cancer metastasis. J Bone Miner Res. 2018;33(12):2099–113. https://doi.org/10.1002/jbmr.3618.CrossRefPubMed

114.

Riebensahm C, Joosse SA, Mohme M, Hanssen A, Matschke J, Goy Y, et al. Clonality of circulating tumor cells in breast cancer brain metastasis patients. Breast Cancer Res. 2019;21(1):11. https://doi.org/10.1186/s13058-019-1184-2.CrossRef

115.

Basudan A, Priedigkeit N, Hartmaier RJ, Sokol ES, Bahreini A, Watters RJ, et al. Frequent ESR1 and CDK pathway copy-number alterations in metastatic breast cancer. Mol Cancer Res. 2019;17(2):457–68. https://doi.org/10.1158/1541-7786.Mcr-18-0946.CrossRefPubMed

116.

Ullah I, Karthik GM, Alkodsi A, Kjallquist U, Stalhammar G, Lovrot J, et al. Evolutionary history of metastatic breast cancer reveals minimal seeding from axillary lymph nodes. J Clin Invest. 2018;128(4):1355–70. https://doi.org/10.1172/jci96149.CrossRefPubMedCentralPubMed

117.

Chiu JH, Wen CS, Wang JY, Hsu CY, Tsai YF, Hung SC, et al. Role of estrogen receptors and Src signaling in mechanisms of bone metastasis by estrogen receptor positive breast cancers. J Transl Med. 2017;15:11. https://doi.org/10.1186/s12967-017-1192-x.CrossRef

118.

Zhang XHF, Wang QQ, Gerald W, Hudis CA, Norton L, Smid M, et al. Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell. 2009;16(1):67–78. https://doi.org/10.1016/j.ccr.2009.05.017.CrossRefPubMedCentralPubMed

119.

Zhang XHF, Jin X, Malladi S, Zou YL, Wen YH, Brogi E, et al. Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. Cell. 2013;154(5):1060–73. https://doi.org/10.1016/j.cell.2013.07.036.CrossRefPubMedCentralPubMed

120.

Ray P, Stacer AC, Fenner J, Cavnar SP, Meguiar K, Brown M, et al. CXCL12-gamma in primary tumors drives breast cancer metastasis. Oncogene. 2015;34(16):2043–51. https://doi.org/10.1038/onc.2014.157.CrossRefPubMed

121.

Siddappa CM, Pillai SG, Snider J, Alldredge P, Trinkaus K, Watson MA, et al. Gene expression analysis to detect disseminated tumor cells in the bone marrow of triple-negative breast cancer patients predicts metastatic relapse. Breast Cancer Res Treat. 2019;178(2):317–25. https://doi.org/10.1007/s10549-019-05405-7.CrossRefPubMedCentralPubMed

122.

Rucci N, Teti A. Osteomimicry: how tumor cells try to deceive the bone. Front Biosci (Schol Ed). 2010;2(3):907–15.PubMed

123.

Bellahcene A, Bachelier R, Detry C, Lidereau R, Clezardin P, Castronovo V. Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells. Breast Cancer Res Treat. 2007;101(2):135–48. https://doi.org/10.1007/s10549-006-9279-8.CrossRefPubMed

124.

Tan CC, Li GX, Tan LD, Du X, Li XQ, He R, et al. Breast cancer cells obtain an osteomimetic feature via epithelial-mesenchymal transition that have undergone BMP2/RUNX2 signaling pathway induction. Oncotarget. 2016;7(48):79674–91. https://doi.org/10.18632/oncotarget.12939.

125.

Chimge NO, Baniwal SK, Little GH, Chen YB, Kahn M, Tripathy D, et al. Regulation of breast cancer metastasis by Runx2 and estrogen signaling: the role of SNAI2. Breast Cancer Res. 2011;13(6):13. https://doi.org/10.1186/bcr3073.CrossRef

126.

Dey N, Barwick BG, Moreno CS, Ordanic-Kodani M, Chen ZJ, Oprea-Ilies G, et al. Wnt signaling in triple negative breast cancer is associated with metastasis. BMC Cancer. 2013;13:15. https://doi.org/10.1186/1471-2407-13-537.CrossRef

127.

Eyre R, Alferez DG, Santiago-Gomez A, Spence K, McConnell JC, Hart C, et al. Microenvironmental IL1 beta promotes breast cancer metastatic colonisation in the bone via activation of Wnt signalling. Nat Commun. 2019;10:15. https://doi.org/10.1038/s41467-019-12807-0.CrossRef

128.

Taipaleenmaki H, Farina NH, van Wijnen AJ, Stein JL, Hesse E, Stein GS, et al. Antagonizing miR-218–5p attenuates Wnt signaling and reduces metastatic bone disease of triple negative breast cancer cells. Oncotarget. 2016;7(48):79018–32. https://doi.org/10.18632/oncotarget.12593.

129.

Hassan MQ, Maeda Y, Taipaleenmaki H, Zhang WB, Jafferji M, Gordon JAR, et al. miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem. 2012;287(50):42084–92. https://doi.org/10.1074/jbc.M112.377515.CrossRefPubMedCentralPubMed

130.

Bendinelli P, Maroni P, Matteucci E, Luzzati A, Perrucchini G, Desiderio MA. Microenvironmental stimuli affect Endothelin-1 signaling responsible for invasiveness and osteomimicry of bone metastasis from breast cancer. Biochim Biophys Acta-Mol Cell Res. 2014;1843(4):815–26. https://doi.org/10.1016/j.bbamcr.2013.12.015.CrossRef

131.

Li XQ, Lu JT, Tan CC, Wang QS, Feng YM. RUNX2 promotes breast cancer bone metastasis by increasing integrin alpha 5-mediated colonization. Cancer Lett. 2016;380(1):78–86. https://doi.org/10.1016/j.canlet.2016.06.007.CrossRefPubMed

132.

Sai BQ, Xiang JJ. Disseminated tumour cells in bone marrow are the source of cancer relapse after therapy. J Cell Mol Med. 2018;22(12):5776–86. https://doi.org/10.1111/jcmm.13867.CrossRefPubMedCentralPubMed

133.

Wang S, Li GX, Tan CC, He R, Kang LJ, Lu JT, et al. FOXF2 reprograms breast cancer cells into bone metastasis seeds. Nat Commun. 2019;10:16. https://doi.org/10.1038/s41467-019-10379-7.CrossRef

134.

Hartkopf AD, Brucker SY, Taran FA, Harbeck N, von Au A, Naume B, et al. Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis. Eur J Cancer. 2021;154:128–37. https://doi.org/10.1016/j.ejca.2021.06.028.CrossRefPubMed

135.

Carlson P, Dasgupta A, Grzelak CA, Kim J, Barrett A, Coleman IM, et al. Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nat Cell Biol. 2019;21(2):238-+. https://doi.org/10.1038/s41556-018-0267-0.

136.

Aguirre-Ghiso JA, Estrada Y, Liu D, Ossowski L. ERKMAPK activity as a determinant of tumor growth and dormancy; Regulation by p38(SAPK). Cancer Res. 2003;63(7):1684–95.PubMed

137.

Bragado P, Estrada Y, Parikh F, Krause S, Capobianco C, Farina HG, et al. TGF-beta 2 dictates disseminated tumour cell fate in target organs through TGF-beta-RIII and p38 alpha/beta signalling. Nat Cell Biol. 2013;15(11):1351-U210. https://doi.org/10.1038/ncb2861.CrossRefPubMedCentralPubMed

138.

Nakamura T, Shinriki S, Jono H, Guo J, Ueda M, Hayashi M, et al. Intrinsic TGF-beta 2-triggered SDF-1-CXCR4 signaling axis is crucial for drug resistance and a slow-cycling state in bone marrow-disseminated tumor cells. Oncotarget. 2015;6(2):1008–19. https://doi.org/10.18632/oncotarget.2826.

139.

Sosa MS, Bragado P, Aguirre-Ghiso JA. Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014;14(9):611–22. https://doi.org/10.1038/nrc3793.CrossRefPubMedCentralPubMed

140.

Phan TG, Croucher PI. The dormant cancer cell life cycle. Nat Rev Cancer. 2020;20(7):398–411. https://doi.org/10.1038/s41568-020-0263-0.CrossRefPubMed

141.

Wang N, Docherty F, Brown HK, Reeves K, Fowles A, Lawson M, et al. Mitotic quiescence, but not unique “stemness”, marks the phenotype of bone metastasis-initiating cells in prostate cancer. Faseb J. 2015;29(8):3141–50. https://doi.org/10.1096/fj.14-266379.CrossRefPubMed

142.

Nobre AR, Risson E, Singh DK, Di Martino JS, Cheung JF, Wang JP, et al. Bone marrow NG2(+)/Nestin(+) mesenchymal stem cells drive DTC dormancy via TGF-beta 2. Nat Cancer. 2021;2(3):327-+. https://doi.org/10.1038/s43018-021-00179-8.

143.

Sandiford OA, Donnelly RJ, El-Far MH, Burgmeyer LM, Sinha G, Pamarthi SH, et al. Mesenchymal stem cell-secreted extracellular vesicles instruct stepwise dedifferentiation of breast cancer cells into dormancy at the bone marrow perivascular region. Cancer Res. 2021;81(6):1567–82. https://doi.org/10.1158/0008-5472.Can-20-2434.CrossRefPubMed

144.

Capulli M, Hristova D, Valbret Z, Carys K, Man R, Maurizi A, et al. Notch2 pathway mediates breast cancer cellular dormancy and mobilisation in bone and contributes to haematopoietic stem cell mimicry. Br J Cancer. 2019;121(2):157–71. https://doi.org/10.1038/s41416-019-0501-y.CrossRefPubMedCentralPubMed

145.

•• Bado IL, Zhang WJ, Hu JY, Xu Z, Wang H, Sarkar P, et al. The bone microenvironment increases phenotypic plasticity of ER+ breast cancer cells. Dev Cell. 2021;56(8):1100-+. https://doi.org/10.1016/j.devcel.2021.03.008. This study shows the transient change of ER expression in the osteogenic niche mediated by epigenetic reprogramming, providing stronger drug resistance and cancer stemness.

146.

Clements ME, Holtslander L, Edwards C, Todd V, Dooyema SDR, Bullock K, et al. HDAC inhibitors induce LIFR expression and promote a dormancy phenotype in breast cancer. Oncogene. 2021;40(34):5314–26. https://doi.org/10.1038/s41388-021-01931-1.CrossRefPubMedCentralPubMed

147.

Huang J, Woods P, Normolle D, Goff JP, Benos PV, Stehle CJ, et al. Downregulation of estrogen receptor and modulation of growth of breast cancer cell lines mediated by paracrine stromal cell signals. Breast Cancer Res Treat. 2017;161(2):229–43. https://doi.org/10.1007/s10549-016-4052-0.CrossRefPubMed

148.

• Zhang WJ, Bado IL, Hu JY, Wan YW, Wu L, Wang H, et al. The bone microenvironment invigorates metastatic seeds for further dissemination. Cell. 2021;184(9):2471-+. https://doi.org/10.1016/j.cell.2021.03.011. An interesting study showing that bone environment enhances the metastatic capacity of bone-metastatic cancer cells, ready for bone macrometastasis and even for further multi-organ metastasis.

149.

Sansone P, Claudio C, Berishaj M, Chang Q, Vinagolu R, Perna F, et al. Self-renewal of CD133hi cells by IL6/Notch3 signaling regulates endocrine resistance in metastatic breast cancers. Cancer Res. 2016;76:3. https://doi.org/10.1158/1538-7445.Am2016-lb-236.CrossRef

150.

Xing F, Okuda H, Watabe M, Kobayashi A, Pai SK, Liu W, et al. Hypoxia-induced Jagged2 promotes breast cancer metastasis and self-renewal of cancer stem-like cells. Oncogene. 2011;30(39):4075–86. https://doi.org/10.1038/onc.2011.122.CrossRefPubMedCentralPubMed

151.

Ono M, Kosaka N, Tominaga N, Yoshioka Y, Takeshita F, Takahashi RU, et al. Exosomes from bone marrow mesenchymal stem cells contain a microRNA that promotes dormancy in metastatic breast cancer cells. Sci Signal. 2014;7(332):10. https://doi.org/10.1126/scisignal.2005231.CrossRef

152.

Lan Q, Peyvandi S, Duffey N, Huang YT, Barras D, Held W, et al. Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer. Oncogene. 2019;38(15):2814–29. https://doi.org/10.1038/s41388-018-0624-2.CrossRefPubMed

153.

Aqbi HF, Coleman C, Zarei M, Manjili SH, Graham L, Koblinski J, et al. Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets. Breast Cancer Res. 2020;22(1):15. https://doi.org/10.1186/s13058-020-01357-9.CrossRef

154.

Buschhaus JM, Humphries BA, Eckley SS, Robison TH, Cutter AC, Rajendran S, et al. Targeting disseminated estrogen-receptor-positive breast cancer cells in bone marrow. Oncogene. 2020;39(34):5649–62. https://doi.org/10.1038/s41388-020-01391-z.CrossRefPubMedCentralPubMed

155.

Liu YY, Lv JD, Liu JY, Liang XY, Jin X, Xie J, et al. STAT3/p53 pathway activation disrupts IFN-beta-induced dormancy in tumor-repopulating cells. J Clin Invest. 2018;128(3):1057–73. https://doi.org/10.1172/jci96329.CrossRefPubMedCentralPubMed

156.

Han HH, Kim BG, Lee JH, Kang S, Kim JE, Cho NH. Angiopoietin-2 promotes ER plus breast cancer cell survival in bone marrow niche. Endocr-Relat Cancer. 2016;23(8):609–23. https://doi.org/10.1530/erc-16-0086.CrossRefPubMedCentralPubMed

157.

Drescher F, Juarez P, Arellano DL, Serafin-Higuera N, Olvera-Rodriguez F, Jimenez S, et al. TIE2 induces breast cancer cell dormancy and inhibits the development of osteolytic bone metastases. Cancers. 2020;12(4):20. https://doi.org/10.3390/cancers12040868.CrossRef

158.

Ghajar CM, Peinado H, Mori H, Matei IR, Evason KJ, Brazier H, et al. The perivascular niche regulates breast tumour dormancy. Nat Cell Biol. 2013;15(7):807-+. https://doi.org/10.1038/ncb2767.

159.

Muscarella AM, Dai W, Mitchell PG, Zhang WJ, Wang H, Jia LY, et al. Unique cellular protrusions mediate breast cancer cell migration by tethering to osteogenic cells. npj Breast Cancer. 2020;6(1):12. https://doi.org/10.1038/s41523-020-00183-8.

160.

Lim PK, Bliss SA, Patel SA, Taborga M, Dave MA, Gregory LA, et al. Gap junction-mediated import of microRNA from bone marrow stromal cells can elicit cell cycle quiescence in breast cancer cells. Cancer Res. 2011;71(5):1550–60. https://doi.org/10.1158/0008-5472.Can-10-2372.CrossRefPubMed

161.

Kolb AD, Shupp AB, Mukhopadhyay D, Marini FC, Bussard KM. Osteoblasts are “educated” by crosstalk with metastatic breast cancer cells in the bone tumor microenvironment. Breast Cancer Res. 2019;21:30. https://doi.org/10.1186/s13058-019-1117-0.CrossRef

162.

Kolb AD, Dai JL, Keller ET, Bussard KM. ‘Educated’ osteoblasts reduce osteoclastogenesis in a bone-tumor mimetic microenvironment. Cancers. 2021;13(2):38. https://doi.org/10.3390/cancers13020263.

163.

Korah R, Boots M, Wieder R. Integrin alpha 5 beta 1 promotes survival of growth-arrested breast cancer cells: an in vitro paradigm for breast cancer dormancy in bone marrow. Cancer Res. 2004;64(13):4514–22. https://doi.org/10.1158/0008-5472.Can-03-3853.CrossRefPubMed

164.

Klein MW, Grujovic A, Obradovic M, Hoffmann M, Lu X, Kirsch S, et al. Interleukin 6 transsignaling is a candidate mechanism to drive progression of human DCCs during periods of clinical latency. Cancer Res. 2019;79(13):2. https://doi.org/10.1158/1538-7445.Am2019-lb-312.CrossRef

165.

Deng R, Zhang HL, Huang JH, Cai RZ, Wang Y, Chen YH, et al. MAPK1/3 kinase-dependent ULK1 degradation attenuates mitophagy and promotes breast cancer bone metastasis. Autophagy. 2021;17(10):3011–29. https://doi.org/10.1080/15548627.2020.1850609.CrossRefPubMed

166.

Ponzetti M, Rucci N. Switching homes: how cancer moves to bone. Int J Mol Sci. 2020;21(11):25. https://doi.org/10.3390/ijms21114124.CrossRef

167.

Hortobagyi GN, Theriault RL, Porter L, Blayney D, Lipton A, Sinoff C, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med. 1996;335(24):1785–91. https://doi.org/10.1056/nejm199612123352401.

168.

Esposito M, Guise T, Kang YB. The biology of bone metastasis. Cold Spring Harb Perspect Med. 2018;8(6):16. https://doi.org/10.1101/cshperspect.a031252.CrossRef

169.

Lu X, Mu E, Wei Y, Riethdorf S, Yang QF, Yuan M, et al. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging alpha 4 beta 1-positive osteoclast progenitors. Cancer Cell. 2011;20(6):701–14. https://doi.org/10.1016/j.ccr.2011.11.002.CrossRefPubMedCentralPubMed

170.

Tsai CF, Chen JH, Wu CT, Chang PC, Wang SL, Yeh WL. Induction of osteoclast-like cell formation by leptin-induced soluble intercellular adhesion molecule secreted from cancer cells. Ther Adv Med Oncol. 2019;11:20. https://doi.org/10.1177/1758835919846806.CrossRef

171.

Mukaida N, Zhang D, Sasaki SI. Emergence of cancer-associated fibroblasts as an indispensable cellular player in bone metastasis process. Cancers. 2020;12(10):18. https://doi.org/10.3390/cancers12102896.CrossRef

172.

•• Wu QY, Tian P, He DS, Jia ZC, He YF, Luo WQ, et al. SCUBE2 mediates bone metastasis of luminal breast cancer by modulating immune-suppressive osteoblastic niches. Cell Res. 2023;33(6):464-78. https://doi.org/10.1038/s41422-023-00810-6. This study investigates the role of ER-regulated SCUBE2 and how osteoblasts promote bone metastasis in an immunomodulatory way.

173.

Coleman RE, Croucher PI, Padhani AR, Clézardin P, Chow E, Fallon M, et al. Bone metastases Nat Rev Dis Primers. 2020;6(1):28. https://doi.org/10.1038/s41572-020-00216-3.CrossRef

174.

Mariathasan S, Turley SJ, Nickles D, Castiglioni A, Yuen K, Wang YL, et al. TGF beta attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;554(7693):544-+. https://doi.org/10.1038/nature25501.

175.

Tauriello DVF, Palomo-Ponce S, Stork D, Berenguer-Llergo A, Badia-Ramentol J, Iglesias M, et al. TGF beta drives immune evasion in genetically reconstituted colon cancer metastasis. Nature. 2018;554(7693):538-+. https://doi.org/10.1038/nature25492.

176.

Sawant A, Deshane J, Jules J, Lee CM, Harris BA, Feng X, et al. Myeloid-derived suppressor cells function as novel osteoclast progenitors enhancing bone loss in breast cancer. Cancer Res. 2013;73(2):672–82. https://doi.org/10.1158/0008-5472.Can-12-2202.CrossRefPubMed

177.

Tan W, Zhang WZ, Strasner A, Grivennikov S, Cheng JQ, Hoffman RM, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470(7335):548–53. https://doi.org/10.1038/nature09707.CrossRefPubMedCentralPubMed

178.

Soderstrom K, Stein E, Colmenero P, Purath U, Muller-Ladner U, de Matos CT, et al. Natural killer cells trigger osteoclastogenesis and bone destruction in arthritis. Proc Natl Acad Sci U S A. 2010;107(29):13028–33. https://doi.org/10.1073/pnas.1000546107.CrossRefPubMed

179.

Zhu L, Hua F, Ding WG, Ding K, Zhang YG, Xu CY. The correlation between the Th17/Treg cell balance and bone health. Immun Ageing. 2020;17(1):10. https://doi.org/10.1186/s12979-020-00202-z.CrossRef

180.

Zaiss MM, Axmann R, Zwerina J, Polzer K, Guckel E, Skapenko A, et al. Treg cells suppress osteoclast formation - a new link between the immune system and bone. Arthritis Rheum. 2007;56(12):4104–12. https://doi.org/10.1002/art.23138.CrossRefPubMed

181.

Francisconi CF, Vieira AE, Azevedo MCS, Tabanez AP, Fonseca AC, Trombone APF, et al. RANKL triggers Treg-mediated immunoregulation in inflammatory osteolysis. J Dent Res. 2018;97(8):917–27. https://doi.org/10.1177/0022034518759302.CrossRefPubMedCentralPubMed

182.

Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, et al. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(1):60–72. https://doi.org/10.1016/s1470-2045(19)30687-4.CrossRefPubMed

183.

Dondossola E, Alexander S, Holzapfel BM, Filippini S, Starbuck MW, Hoffman RM, et al. Intravital microscopy of osteolytic progression and therapy response of cancer lesions in the bone. Sci Transl Med. 2018;10(452):10. https://doi.org/10.1126/scitranslmed.aao5726.CrossRef

184.

Zhang KH, Kim S, Cremasco V, Hirbe AC, Novack DV, Weilbaecher K, et al. CD8(+) T cells regulate bone tumor burden independent of osteoclast resorption. Cancer Res. 2011;71(14):4799–808. https://doi.org/10.1158/0008-5472.Can-10-3922.CrossRefPubMedCentralPubMed

185.

Sun X, Li KX, Zha RR, Liu SZ, Fan Y, Wu D, et al. Preventing tumor progression to the bone by induced tumor-suppressing MSCs. Theranostics. 2021;11(11):5143–59. https://doi.org/10.7150/thno.58779.CrossRefPubMedCentralPubMed

186.

Sun X, Li KX, Hase M, Zha RR, Feng Y, Li BY, et al. Suppression of breast cancer-associated bone loss with osteoblast proteomes via Hsp90ab1/moesin-mediated inhibition of TGF beta/FN1/CD44 signaling. Theranostics. 2022;12(2):929–43. https://doi.org/10.7150/thno.66148.CrossRefPubMedCentralPubMed

187.

Li KX, Sun X, Li BY, Yokota H. Conversion of osteoclasts into bone-protective, tumor-suppressing cells. Cancers. 2021;13(22):18. https://doi.org/10.3390/cancers13225593.CrossRef

188.

Gillespie EF, Yang JC, Mathis NJ, Marine CB, White C, Zhang Z, et al. Prophylactic radiation therapy versus standard of care for patients with high-risk asymptomatic bone metastases: a multicenter, randomized phase II clinical trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2023:JCO2300753. https://doi.org/10.1200/jco.23.00753.

189.

Hofbauer LC, Bozec A, Rauner M, Jakob F, Perner S, Pantel K. Novel approaches to target the microenvironment of bone metastasis. Nat Rev Clin Oncol. 2021;18(8):488–505. https://doi.org/10.1038/s41571-021-00499-9.CrossRefPubMed

190.

Ihle CL, Wright-Hobart SJ, Owens P. Therapeutics targeting the metastatic breast cancer bone microenvironment. Pharmacol Ther. 2022;239:14. https://doi.org/10.1016/j.pharmthera.2022.108280.CrossRef

191.

Tian ZR, Yu CF, Zhang WJ, Wu KL, Gupta R, Xu Z, et al. Bone-specific enhancement of antibody therapy for breast cancer metastasis to bone. ACS Central Sci. 2022;8(3):312–21. https://doi.org/10.1021/acscentsci.1c01024.CrossRef

192.

Li ZF, Liu PX, Chen W, Liu XY, Tong F, Sun JH, et al. Hypoxia-cleavable and specific targeted nanomedicine delivers epigenetic drugs for enhanced treatment of breast cancer and bone metastasis. J Nanobiotechnol. 2023;21(1):14. https://doi.org/10.1186/s12951-023-01939-7.CrossRef

193.

Sun WT, Ge K, Jin Y, Han Y, Zhang HS, Zhou GQ, et al. Bone-targeted nanoplatform combining zoledronate and photothermal therapy to treat breast cancer bone metastasis. ACS Nano. 2019;13(7):7556–67. https://doi.org/10.1021/acsnano.9b00097.CrossRefPubMed

194.

Zeng YX, Pan ZX, Yuan JP, Song YQ, Feng ZZ, Chen ZF, et al. Inhibiting osteolytic breast cancer bone metastasis by bone-targeted nanoagent via remodeling the bone tumor microenvironment combined with NIR-II photothermal therapy. Small. 2023:24. https://doi.org/10.1002/smll.202301003.

195.

Sun PF, Qu F, Zhang C, Cheng PF, Li XY, Shen QM, et al. NIR-II Excitation phototheranostic platform for synergistic photothermal therapy/chemotherapy/chemodynamic therapy of breast cancer bone metastases. Adv Sci. 2022;9(33):12. https://doi.org/10.1002/advs.202204718.CrossRef

196.

Shen YP, Zou Y, Bie BL, Lv YG. Hierarchically Released Liquid Metal Nanoparticles for mild photothermal therapy/chemotherapy of breast cancer bone metastases via remodeling tumor stromal microenvironment. Adv Healthc Mater. 2023:14. https://doi.org/10.1002/adhm.202301080.

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The Role of Breast Cancer Cells in Bone Metastasis: Suitable Seeds for Nourishing Soil

Abstract

Purpose of Review

Recent Findings

Summary

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 1/2024

The Utility of AI in Writing a Scientific Review Article on the Impacts of COVID-19 on Musculoskeletal Health

Do Not Lose Your Nerve, Be Callus: Insights Into Neural Regulation of Fracture Healing

The Bone-Vascular Axis in Chronic Kidney Disease: From Pathophysiology to Treatment

Using AI to Write a Review Article Examining the Role of the Nervous System on Skeletal Homeostasis and Fracture Healing

Quantitative Skeletal Imaging and Image-Based Modeling in Pediatric Orthopaedics

From the Mind to the Spine: The Intersecting World of Alzheimer’s and Osteoporosis